TASE approves new listing of PROLOR Biotech’s common stock

TASE approves new listing of PROLOR Biotech’s common stock
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, this day announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR’s common stock on the TASE beginning on Thursday, Might 27, 2010. At that time, the company’s common stock will be listed on both the NYSE Amex in the United Says and the TASE in Israel.

Read more on News-Medical-Net

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …
D-Pharm Ltd (DPRM: TASE) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for a pivotal phase 3 trial (MACSI) of its neuroprotective agent DP-b99 in acute ischemic stroke patients. The SPA agreement letter indicates that “the design and planned analysis of the study adequately address the objectives …

Read more on Medical News Today